Ovarian cancer patients with BRCA1 or BRCA2 mutations more likely to survive

Ovarian cancer patients who carry BRCA1 or BRCA2 mutations are significantly more likely to survive the disease than women without these faulty genes, according to research published in the Journal of the American Medical Association.

Ovarian cancer screening doesn't save lives: Study

Berg said that it's possible that a modified form of the blood test -- which looks for a protein that hints at the presence of ovarian cancer cells -- will help doctors identify early cases of ovarian cancer.

Cynthia Nixon in Broadway's 'Wit': The essence of a naked performance

From the first moments, Cynthia Nixon gives an exceptionally brave performance in her 40th play. All I could think was how naked she was, though cloaked in two hospital gowns, socks and a red baseball cap. Her head is shaved and she is there to die from Stage 4 ovarian cancer.

Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years

( JAMA and Archives Journals ) Among women with invasive epithelial ovarian cancer, patients having a germline (gene change in a reproductive cell that could be passed to offspring) mutation in the BRCA1 or BRCA2 genes was associated with improved five-year overall survival, with BRCA2 carriers having the best prognosis, according to a study in the Jan. 25 issue of JAMA.

Broadway Review: ‘Wit’

The potent Wit is the only play Margaret Edson wrote, and you could say she quit while she was on top of her game. Her story of a callous, didactic scholar battling stage-4 ovarian cancer won the Pulitzer Prize in 1999 and has been produced by theaters all over the country.